1. Genetics and Genomics
  2. Medicine

Genetic identification of a common collagen disease in Puerto Ricans via identity-by-descent mapping in a health system

  1. Gillian Morven Belbin
  2. Jacqueline Odgis
  3. Elena P Sorokin
  4. Muh-Ching Yee
  5. Sumita Kohli
  6. Benjamin S Glicksberg
  7. Christopher R Gignoux
  8. Genevieve L Wojcik
  9. Tielman Van Vleck
  10. Janina M Jeff
  11. Michael Linderman
  12. Claudia Schurmann
  13. Douglas Ruderfer
  14. Xiaoqiang Cai
  15. Amanda Merkelson
  16. Anne E Justice
  17. Kristin L Young
  18. Misa Graff
  19. Kari E North
  20. Ulrike Peters
  21. Regina James
  22. Lucia Hindorff
  23. Ruth Kornreich
  24. Lisa Edelmann
  25. Omri Gottesman
  26. Eli EA Stahl
  27. Judy H Cho
  28. Ruth JF Loos
  29. Erwin P Bottinger
  30. Girish N Nadkarni
  31. Noura S Abul-Husn
  32. Eimear E Kenny  Is a corresponding author
  1. Icahn School of Medicine at Mount Sinai, United States
  2. Stanford University School of Medicine, United States
  3. Carnegie Institution for Science, United States
  4. Icahn School of Medicine at Mt Sinai, United States
  5. Broad Institute, United States
  6. University of North Carolina at Chapel Hill, United States
  7. Fred Hutchinson Cancer Research Center, United States
  8. University of Washington School of Public Health, United States
  9. National Institute on Minority Health and Health Disparities, National Institutes of Health, United States
  10. National Human Genome Research Institute, National Institutes of Health, United States
https://doi.org/10.7554/eLife.25060
Share this article
Cite this article
  1. Gillian Morven Belbin
  2. Jacqueline Odgis
  3. Elena P Sorokin
  4. Muh-Ching Yee
  5. Sumita Kohli
  6. Benjamin S Glicksberg
  7. Christopher R Gignoux
  8. Genevieve L Wojcik
  9. Tielman Van Vleck
  10. Janina M Jeff
  11. Michael Linderman
  12. Claudia Schurmann
  13. Douglas Ruderfer
  14. Xiaoqiang Cai
  15. Amanda Merkelson
  16. Anne E Justice
  17. Kristin L Young
  18. Misa Graff
  19. Kari E North
  20. Ulrike Peters
  21. Regina James
  22. Lucia Hindorff
  23. Ruth Kornreich
  24. Lisa Edelmann
  25. Omri Gottesman
  26. Eli EA Stahl
  27. Judy H Cho
  28. Ruth JF Loos
  29. Erwin P Bottinger
  30. Girish N Nadkarni
  31. Noura S Abul-Husn
  32. Eimear E Kenny
(2017)
Genetic identification of a common collagen disease in Puerto Ricans via identity-by-descent mapping in a health system
eLife 6:e25060.
https://doi.org/10.7554/eLife.25060
  2. Download BibTeX
  3. Download .RIS

Abstract

Achieving confidence in the causality of a disease locus is a complex task that often requires supporting data from both statistical genetics and clinical genomics. Here we describe a combined approach to identify and characterize a genetic disorder that leverages distantly related patients in a health system and population-scale mapping. We utilize genomic data to uncover components of distant pedigrees, in the absence of recorded pedigree information, in the multi-ethnic BioMe biobank in New York City. By linking to medical records, we discover a locus associated with both elevated genetic relatedness and extreme short stature. We link the gene, COL27A1, with a little-known genetic disease, previously thought to be rare and recessive. We demonstrate that disease manifests in both heterozygotes and homozygotes, indicating a common collagen disorder impacting up to 2% of individuals of Puerto Rican ancestry, leading to a better understanding of the continuum of complex and Mendelian disease.

https://doi.org/10.7554/eLife.25060.001

eLife digest

Diseases often run in families. These disease are frequently linked to changes in DNA that are passed down through generations. Close family members may share these disease-causing mutations; so may distant relatives who inherited the same mutation from a common ancestor long ago. Geneticists use a method called linkage mapping to trace a disease found in multiple members of a family over generations to genetic changes in a shared ancestor. This allows scientists to pinpoint the exact place in the genome the disease-causing mutation occurred. Using computer algorithms, scientists can apply the same technique to identify mutations that distant relatives inherited from a common ancestor.

Belbin et al. used this computational technique to identify a mutation that may cause unusually short stature or bone and joint problems in up to 2% of people of Puerto Rican descent. In the experiments, the genomes of about 32,000 New Yorkers who have volunteered to participate in the BioMe Biobank and their health records were used to search for genetic changes linked to extremely short stature. The search revealed that people who inherited two copies of this mutation from their parents were likely to be extremely short or to have bone and joint problems. People who inherited one copy had an increased likelihood of joint or bone problems.

This mutation affects a gene responsible for making a form of protein called collagen that is important for bone growth. The analysis suggests the mutation first arose in a Native American ancestor living in Puerto Rico around the time that European colonization began. The mutation had previously been linked to a disorder called Steel syndrome that was thought to be rare. Belbin et al. showed this condition is actually fairly common in people whose ancestors recently came from Puerto Rico, but may often go undiagnosed by their physicians. The experiments emphasize the importance of including diverse populations in genetic studies, as studies of people of predominantly European descent would likely have missed the link between this disease and mutation.

https://doi.org/10.7554/eLife.25060.002

Introduction

During the past two decades major advances in deciphering the genetic basis of human disease have resulted in thousands of disorders that are now understood at a genetic level (Hamosh et al., 2000; McCarthy et al., 2013). This progress has led to the integration of genomic sequencing in clinical care, especially for the diagnosis of rare genetic disease (Bamshad et al., 2011; Manolio et al., 2013), and clinical sequencing is increasingly offered to patients with known or suspected genetic disorders. In the past few years, large national and international efforts (Manolio et al., 2015; Philippakis et al., 2015; Chong et al., 2015a) have emerged to enable patients and health systems to share knowledge of rare genetic disorders and improve genetic testing, resulting in improved healthcare management and outcomes for patients. In parallel, many large regional and national biobank efforts (Collins and Varmus, 2015; Ashley, 2015; Collins, 2012) are underway to enable the broad integration of genomics in health systems for genetic identification of disease (Dewey et al., 2016). Such efforts have recently revealed clinically actionable variants (Dewey et al., 2016; Feldman, 2016) and genetic disorders segregating at higher frequencies in general patient populations than previously suspected. The increased promulgation of genomics in health systems represents an opportunity to improve diagnostic sensitivity for more precise therapeutic intervention and better health outcomes (Ashley, 2016).

Despite this progress, most genetic diseases are still under-diagnosed (Abul-Husn et al., 2016) or misdiagnosed (Yang et al., 2014; Taylor et al., 2015; Centers for Mendelian Genomics et al., 2015b). A number of barriers exist for wholesale genetic testing and diagnoses, including incomplete standardized guidelines for interpreting genetic evidence of disease (Amendola et al., 2016), variable penetrance or expressivity of phenotype (Katsanis, 2016), and that the causal variant may be missed or mis-assigned during testing (Manrai et al., 2016). The latter is a particularly pernicious problem in non-European populations due to systematic biases in large genomic and clinical databases (Popejoy and Fullerton, 2016; Petrovski and Goldstein, 2016). These challenges have led several research groups to attempt to genetically identify disease by examining patient health patterns using data from the Electronic Health Record (EHR) (Gottesman et al., 2013; Green et al., 2016). EHRs contain comprehensive information on medical care throughout a patient’s life, including medications, medical billing codes, physician notes and generated reports (i.e. pathologic, genetic and radiologic reports). EHRs have been used to clinically characterize well-known genetic disorders, but have been of limited success for the vast cadre of less-characterized or unknown disorders (Blair et al., 2013).

The gold standard of genetic disorder diagnosis involves testing both patient and family members to confirm Mendelian segregation of the suspected underlying pathogenic variant (ClinGen et al., 2015; ClinGen Resource et al., 2015; Gahl et al., 2016). However, as genomic data becomes more ubiquitous in health systems, it can be used to detect genetic relationships in the absence of known family and pedigree information. Specifically, components of pedigrees can be uncovered within the general population; particularly those that have experienced recent founder effects. Pairs of individuals who are related share genetic homology in the form of long genomic haplotypes. These haplotypes are considered to be identical-by-descent (IBD) if they are inherited from a common ancestor without any intervening recombination. The chance of any two people sharing a tract of their genome IBD decays exponentially, with a ~50% reduction in the chance of sharing per generation. However, when IBD sharing does occur, the length of an IBD segment can remain long even between distantly related individuals. In practice, long tracts of IBD (>3 cM) can be accurately detected using genetic data between individuals with a common ancestor from the past 4–50 generations (Browning and Browning, 2012). Detection of IBD haplotypes can allow for the identification of distantly related patients with a genetic disorder driven by a locus inherited from a founding ancestor who brought the disease mutation into a population (Houwen et al., 1994; Kenny et al., 2009; Henden et al., 2016; Meta-Analysis of Glucose and Insulin-related traits Consortium (MAGIC) et al., 2010; Traherne et al., 2016; Shaw et al., 2015; Ko et al., 2014; Lalli et al., 2014). This is the principle underlying population-scale disease mapping approaches that combine IBD sharing and statistical association to discover novel disease loci, so called IBD-mapping.

By detecting genetic relatedness, as inferred by IBD sharing, we hypothesized that we may be able to detect hereditary forms of disease in an EHR-linked biobank. With over 38000 participants, the BioMe biobank, at the Icahn School of Medicine at Mount Sinai, New York City (NYC), is one of the most diverse cohorts ascertained at a single urban medical center under a uniform study protocol. Participants are largely from the local Upper East Side, Harlem and Bronx communities, and represent broad ancestral, ethnic, cultural, and socioeconomic diversity. We initially focused on adult height, which is easily measurable, stable over the adult life course, and one of the most abundantly recorded clinical parameters in EHRs. Height is known to be highly heritable and polygenic (Visscher et al., 2010; Lango Allen et al., 2010), however, extremes of short stature can be caused by rare variants in single genes with large effect sizes (Durand and Rappold, 2013a). Although, many genetic syndromes are known to cause short stature, most of the time no definitive etiology underlying short stature is found in patients. Here we used loci associated with elevated genetic relatedness as measured by IBD to map a locus underlying extreme short stature in the BioMe biobank, and linked it to a known, but little characterized, collagen disorder previously thought to be rare. By interrogating a large global diversity panel, we demonstrated that this variant is actually common in Puerto Rican populations. Furthermore, we leveraged the EHR to show significant musculoskeletal disease in both heterozygous and homozygous patients, indicating the disease is not simply a recessive disorder as had previously been thought. Finally, we showed how this work can generate broad insights for sustainable adoption and large-scale dissemination of genomic medicine.

Results

Detecting patterns of diversity, founder effects and relatedness in the BioMe biobank from New York City

The BioMe biobank comprises a highly diverse cohort, with over 65% of participants self-reporting as Black/African-American or Hispanic/Latino/a, and over 35% born outside mainland US, representing more than 110 countries of origin. First we estimated patterns of direct relatedness in a subset of BioMe participants genotyped on the Illumina OmniExpress array (N = 11212) by detecting pairwise identity-by-state using RELATEAdmix (Moltke and Albrechtsen, 2014), a method that accounts for admixture in populations (Figure 1—figure supplement 1). We observed that 701 individuals had primary (parent-child, sibling) or secondary (avuncular, grandparental) relationship with another participant in BioMe, and we removed these individuals from all downstream analysis. Next we devised a strategy to divide the diverse BioMe biobank into population groups for downstream analysis. We combined genotype data for BioMe participants (N = 10511) with 26 global populations from the 1000 Genomes Project (1KGP; N = 2504) (The 1000 Genomes Project Consortium, 2015) and two additional panels of Native American (N = 43) (Mao et al., 2007) and Ashkenazi Jewish populations (N = 100) (see Methods). Using a common set of 174468 SNPS we performed principal component analysis (Price et al., 2006) (PCA; Figure 1—figure supplement 2). Based on both self-reporting and patterns of genetic diversity observed in BioMe participants, we stratified individuals into four broad population groups. The first group self-reported as European American, but were also genetically identified as Ashkenazi Jewish (AJ; N = 808) as they clustered distinctly with an AJ reference panel and separately from other European ancestry groups in PCA space (Figure 1—figure supplement 3). The other three groups we defined using self-reported race/ethnicity categories, African-American (AA; N = 3080), Hispanic/Latino/a (H/L; N = 5102) and European-Americans with no AJ genetic ancestry (Non-AJ EA; N = 1270) (Figure 1—figure supplement 3). An additional 251 individuals who reported ‘Mixed’ (N = 89) or ‘Other’ (N = 162) ethnicity were excluded from further analysis.

To evaluate signatures of distant relatedness BioMe biobank participants, we estimated sharing of genomic tracts IBD >3 cM between every pair of individuals using the GERMLINE software (Gusev et al., 2009). The minimum length of 3 cM was chosen based on reports of elevated type I error in call rates of smaller lengths (Gusev et al., 2012; Chiang et al., 2016). It is known that population-level rates of distant relatedness are observed to be particularly elevated after population bottlenecks (i.e. in founder populations) (Browning and Thompson, 2012). We summed the length of all IBD-tracts shared between a given pair of individuals if they shared more than one tract and examined the distribution of pairwise sharing at a population level. We observed elevated levels of distant relatedness in both the AJ (median summed length of IBD sharing within population = 44.7 cM; 95% C.I. = 44.66–44.82 cM) and HL (16.2 cM; 16.18–16.22 cM) populations, compared to AA (3.77 cM; 3.76–3.77 cM) or non-AJ EA (4.5 cM; 4.45–4.55 cM) populations (Figure 1A). This is congruent with previous reports of founder effects in both AJ populations (Need et al., 2009) and in some H/L populations (Moreno-Estrada et al., 2013).

Figure 1 with 4 supplements see all
Download asset Open asset
Distribution of Identity-by-Descent sharing among BioMe populations.

(A) Distribution of the pairwise sum of Identity-by-Descent (IBD) sharing (cM) between four broadly defined BioMe populations, namely; African American (AA), Ashkenazi Jewish (AJ), Hispanic/Latino/a (H/L) and Non-Jewish European American (Non-AJ EA). (B) Sub-continental diversity in self-reported H/L participants in BioMe. Afro-Caribbean participants fall between European (red) and African (blue) continental reference panels, Mexican and Central/South American H/L participants fall between European and Native American (green) reference panels, mainland US-born participants reside on either cline. (C) The tract length distribution of IBD sharing among BioMe populations, normalized by population size. The y-axis represents the proportion population-level sharing (x / (N*(N-1)/2)), where x is the sum of the number of pairwise shared IBD tracts and N is the number of individuals per population. The AJ population exhibits the highest level of population level sharing, followed by Puerto Rican born H/L.

https://doi.org/10.7554/eLife.25060.003

Hispanic or Latino/a is a broad ethnic label encompassing myriad populations with origins in Northern, Southern or Central America, century-long roots in New York City, and genetic ancestry from Africa, Europe and the Americas. To explore the signature of a founder effect in the BioMe H/L population, we leveraged self-reported and genetic information about sub-continental ancestry. By self-reporting, the H/L participants in BioMe were born in New York City (NYC) (40%), Puerto Rico (24%), Dominican Republic (19%), Central/South America (12%), Mexico (2%) or other Caribbean Island (2%) (Figure 1B). We examined IBD tract length distributions within H/L sub-continental populations and observed that the founder effect was predominantly driven in the Puerto Rican-born group (Figure 1C). We assembled a cohort of Puerto Ricans including BioMe participants who were either born in Puerto Rico or, were born in NYC and had 2 parents or 3–4 grand parents who were born in Puerto Rico (N = 1245). Approximately 5086 NYC-born H/L individuals did not have recorded parental or grandparental country-of-origin, therefore we also devised a selection strategy using PCA analysis. We identified BioMe H/L participants on the cline between the African and European reference panels in PCA space coincident with Puerto Rican-born individuals. We excluded those on the same cline with ancestry from the Dominican Republic or another Caribbean Island (Figure 1—figure supplement 4), and counted the remainder (N = 1571) in the Puerto Rican group. In total, we estimated 2816 H/L in the BioMe discovery cohort were of Puerto Rican ancestry, and focused the downstream analysis on this group as the largest founder population in BioMe.

Detecting a locus shared identical-by-descent underlying extreme short stature in Puerto Ricans

Next we tested the hypothesis that rare, recessive disease variants may have arisen to appreciable frequency in the Puerto Rican founder population. We linked genomic data to clinical data in the Electronic Health Record (EHR) of the Mount Sinai Health System. We focused on height, a stable and ubiquitous health measure. Clinically, rare instances of growth failure or ‘short stature’ may be caused by a large heterogeneous group of genetic disorders (i.e. skeletal dysplasias) (Durand and Rappold, 2013b). We first extracted measures of height for the Puerto Rican adult population of BioMe (mean age = 55.3, standard deviation (s.d.)=16.1). After making exclusions based on age (>=18 years old for women, >=22 years old for men, and <80 years old in both sexes, 194 individuals in total), mean height measurements (mean height = 5’ 8.2’, s.d. = 3.2’ for men; mean height = 5’ 2.8’ s.d. = 2.8’ for women) were consistent with those reported for Puerto Rican populations in a recent global study on height (NCD Risk Factor Collaboration (NCD-RisC), 2016). We noted that 56 Puerto Ricans met the clinical definition of short stature (Cohen et al., 2008) (range of short stature 5’1’−4’0’ in men, and 4’8’−3’8’ in women) defined as 2 standard deviations below the population-specific mean for men and women separately (Figure 2—figure supplement 1).

To test for recently arisen, recessive variants underlying clinical short stature in Puerto Ricans, we implemented a previously published pipeline for ‘IBD mapping’ (Kenny et al., 2009; Vacic et al., 2014) (Figure 2—figure supplement 2). We first clustered participants into ‘cliques’ of 3 or more individuals whom, at a given genomic region, shared overlapping homologous IBD tracts of at least 0.5 cM in length in either a heterozygous or homozygous state. Membership in a clique indicates the sharing of a recent common ancestor at that locus, from which the homologous IBD tract was jointly inherited. Clustering of IBD into cliques in the Puerto Rican population (N = 2816) yielded 1434421 IBD-cliques after quality control filters (see Methods). The site frequency spectrum of IBD-cliques (Figure 2—figure supplement 3) demonstrates an expected exponential distribution of clique sizes (of 3–77 haplotypes), representing a class of rare IBD haplotypic alleles (allelic frequency 0.0005–0.0137). To test whether any cliques of IBD haplotypes were significantly associated with height we performed genome-wide association of height as a continuous trait under a recessive model using PLINKv1.9 (Purcell et al., 2007; Chang et al., 2015), including the first five PCA eigenvectors as covariates (see Materials and methods). We restricted analysis to 480 out of 1434421 cliques that contained at least 3 individuals who were homozygous for the shared haplotype. Adjusting for 480 tests (Bonferroni adjusted threshold p<1×10−4) one IBD-clique achieved a genome-wide significant signal at the locus 9q32 (IBD-clique frequency = 0.012; β = −3.78; p<2.57×10−11) (Figure 2A), spanning a large mapping interval chr9:112 MB-120MB. The clique contains 59 individuals, 56 of whom are heterozygous and 3 are homozygous for the associated IBD haplotype.

Figure 2 with 7 supplements see all
Download asset Open asset
Identity-by-Descent mapping reveals locus associated with short stature.

(A) Identity-By-Descent (IBD) mapping for height in BioMe Puerto Ricans using a recessive model. Analysis was restricted to IBD-cliques where at least three individuals were homozygous. Only one IBD-clique achieved Bonferroni significance (at 9q32). (B) Distribution of height among Puerto Rican individuals who carry either 0,1 or 2 copies of the IBD-haplotype reveals a large recessive effect. Homozygous individuals (those carrying 2 copies of the IBD-haplotype) are on average 6–10’ shorter than the population mean for Puerto Rican ancestry individuals. (C) The minimum shared boundary of the significant IBD-haplotype between the three homozygous individuals (represented by the dashed blue line). The top panel depicts known genes at the 9q32 locus. The minimum shared boundary of the IBD overlaps the gene COL27A1..

https://doi.org/10.7554/eLife.25060.008

Fine-mapping short stature locus reveals putative link to mendelian syndrome

The three individuals driving the recessive signal, two women and one man, were less than 2.5 s.d. shorter (height reduction range 6’−10’) than the population mean for height in the Puerto Rican cohort (Figure 2B). The IBD-haplotypes driving the signal spanned a genic region with several candidate loci, and the minimum shared boundary overlapped a single gene, COL27A1, which encodes for Collagen Type XXVII, Alpha 1 (Figure 2C). We performed whole genome sequencing (WGS) of the three homozygous individuals, and an additional short-statured individual that we observed to possess a homozygous IBD haplotype that was both directly upstream of and highly correlated with the top IBD-clique. Individuals were sequenced to a depth of 4-18X coverage (Supplementary file 1). Examination of variants that were observed in at least 6 copies between the four individuals (to account for sequencing error or missing calls) revealed a single candidate coding allele, a missense mutation in Collagen Type XXVII, Alpha 1 (COL27A1, g.9:116958257.C>G, NM_032888.1, p.G697R, rs140950220) (Supplemental file 2). In silico analysis suggest that this glycine residue is highly conserved, and that a molecular alteration to arginine at this position is predicted to be damaging (SIFT score = 0.0; PhyloP score = 2.673; GERP NR score = 5.67). These findings are consistent with a recent report implicating the same COL27A1 variant as causal for the rare orthopedic condition Steel syndrome in a Puerto Rican family (Gonzaga-Jauregui et al., 2015). First described in 1993, the main clinical features of Steel syndrome include short stature, bilateral hip and radial head dislocations, carpal coalition (fusion of the carpal bones), scoliosis, pes cavus (high arches), and dysmorphic features (Steel et al., 1993).

To confirm the link between the IBD haplotype and the putative causal variant, we calculated the concordance between the IBD haplotype and carrier status of the COL27A1.pG697R variant by genotyping all of the homozygotes and carriers of the top IBD-clique in the recessive model (N = 59), along with a panel of age- and sex-matched controls (N = 59). This demonstrated 100% concordance between the COL27A1.pG697R variant and the significant IBD-haplotype in homozygotes (Supplementary file 3). We note that two Puerto Rican participants in the phase 3 1KGP reference panel were carriers of the COL27A1.pG697R variant, raising the possibility that we may have been able to detect this association using more a traditional SNP association approach. Therefore, we performed genome-wide association in the same Puerto Rican cohort (N = 2622) by first imputing the 1KGP panel and re-running the recessive test as described above (n = 10007795 imputed and genotyped SNPs with an INFO score of >0.3 and at least two observations of homozygotes). The recessive model appeared to be well calibrated (λ = 1.02), however, we observed no genome-wide significant signal (Figure 2—figure supplement 4). Association with the COL27A1.pG697R variant was the 11775th most significant association (MAF = 0.014: β = −3.0; p<0.001). Upon examination of the correlation between the imputed COL27A1.pG697R and the true carrier status of homozygotes, we noted a concordance of only 66.67%, indicating that the IBD haplotype was a better tag of the true COL27A1.pG697R homozygous state compared to 1KGP imputation in the Puerto Rican cohort (Supplemental file 3).

The association between COL27A1.pG697R and clinical short stature was replicated using a cohort of 1775 individuals of self-reported Puerto Rican ancestry from BioMe that were not included in the discovery analysis, that were genotyped on the Illumina Infinium Multi-Ethnic Genotype Array (MEGA) as part of the Polygeneic Architecture using Genomics and Epidemiology (PAGE) Study. The COL27A1.pG697R (rs140950220) variant was directly genotyped on MEGA, and an association of the variant under a recessive model resulted in a strong signal of association (allele frequency = 0.017; β = −3.5; s.e. = 0.70; p<4.87×10−07). The replication analysis revealed 51 additional BioMe carriers and two individuals that were homozygous for the variant. Both carrier and affected status was confirmed via independent genotyping and Sanger sequencing (see Materials and methods). The two homozygous participants were both short statured (2.4 and 3.6 s.d from the sex specific population mean).

Evidence from electronic health records supports suspected cases of steel syndrome

To determine whether there was any clinical evidence to validate the link between the COL27A1.pG697R variant and Steel syndrome, a clinical expert manually reviewed the electronic health records (EHR), including clinical diagnoses, surgical procedures, and radiology reports of the five participants (3 women, 2 men, age range 34–74 years) homozygous for the COL27A1.pG697R variant that we had identified through the discovery and replication efforts. Of note, there was no evidence that any of the five patients had a clinical diagnosis of Steel syndrome. In all five individuals, however, we found EHR-documented evidence of several previously described Steel syndrome characteristics, including developmental dysplasia of the hip (or congenital hip dysplasia), carpal coalition, scoliosis, and cervical spine anomalies (Table 1) (Steel et al., 1993; Flynn et al., 2010). The incidence of cervical spine anomalies, including cord compression and spine surgeries, was higher than previously reported (four out of five patients). There was also evidence of other significant musculoskeletal complications, including lumbar and thoracic spine anomalies in three patients, knee replacements in two patients (both under age 50), and joint degeneration or arthritis in four patients. Together, these data help further our understanding of Steel syndrome-associated characteristics and potential complications that can occur later in life.

Table 1
Clinical characteristics of five BioMe participants homozygote, thirty-four carriers and thirty-one non-carriers of the COL27A1.pG697R variant using evidence documented in Electronic Health Records (including billing and procedural codes, laboratory, radiologic, and progress notes) compared to features previously reported in Flynn et al. (2010), and Steel et al., 1993 for 27 children and 7 adults with Steel syndrome.
https://doi.org/10.7554/eLife.25060.016
CharacteristicsEHR-Documented evidenceLiteratureHomozygous childrenLiteratureHomozygous AdultsBioMeHomozygousAdultsBioMeHeterozygousAdults <55yoaBioMeControlsAdults <55yoa
Sample size (Gender)N (N of females)27 (9)7(6)5 (3)34(20)31(23)
AgeMean age (years)12.835.451.641.840.6
Described CharacteristicsEHR-Documented Medical HistoryN(%)N(%)N(%)N(%)N(%)
Short StatureHeight >= 2 s.d. from pop mean27 (100)7 (100)5 (100)0 (0)0 (0)
Bilateral hip dislocationCongenital hip dislocation400
Leg length discrepancy100
Total27(100)7(100)5 (100)0 (0)0 (0)
Radial head dislocationElbow contractures24 (89)7 (100)1 (20)0 (0)0 (0)
Carpal coalitionWrist deformity121
Lunotriquetial fusion100
Carpel tunnel033
Total24 (89)6 (86)2 (40)5(15)4(13)
ScoliosisScoliosis12 (44)6 (86)2 (40)8 (24)4 (13)
Pes cavusPes cavus12 (44)0 (0)0 (0)0 (0)0 (0)
Cervical spine anomaliesCervical stenosis350
Cervical discitis100
Cervical spondylosis273
Cervical cord compression331
Total3 (9)0 (0)4 (80)7 (21)3 (10)
Other CharacteristicsEHR-Documented Medical HistoryN(%)N(%)N(%)
Other spine anomaliesLumbar spine--1 (20)10 (29)5 (16)
Thoracic spine--1 (20)5(15)4(13)
Other skeletal diseaseOsteoporosis or osteopenia--3 (60)3(9)1 (3)
Arthritis or degenerative changes--3 (60)13(38)6 (19)
Relevant surgical InterventionsHip replacement--3 (60)0 (0)0 (0)
Knee replacement--2 (40)0 (0)0 (0)
Cervical spine--3 (60)2 (6)1 (3)
Lumbar spine--1 (20)1 (3)0 (0)
Thoracic spine--2 (40)1 (3)1 (3)

Functional Investigation of COL27A1.pG697R

To understand the biological mechanism underlying Steel syndrome, we investigated the functional role of the COL27A1 gene. COL27A1 is a fibrillar collagen, which are a class of collagens that contribute to the structural integrity of the extracellular matrix (Pace et al., 2003). Enrichment of COL27A1 RNA expression in vertebrae, as well as long bones, eyes, and lungs has previously been observed in embryonic mice (Pace et al., 2003). A mouse deletion of 87 amino acids of the COL27A1 homolog exhibited severe chondroplasia consistent with clinical features observed in homozygotes (Plumb et al., 2011), a similar musculoskeletal phenotype was observed in knockdown of the col27a1a and col27a1b genes in zebrafish (Christiansen et al., 2009). Type alpha-1 collagen genes, of which COL27A1 is a member, contain a conserved Gly-Xaa-Yaa repeat in their triple helical domain (Persikov et al., 2004). Therefore, we hypothesized that the COL27A1.pG697R variant may similarly disrupt stability of the COL27A1 triple helix.

To test this hypothesis we modeled the effect of a glycine-to-arginine substitution in the structure of a prototypical collagen peptide (Bella et al., 1994). We observed that the glycine residues occupied the center of the crowded triple helix, and that substitution for a bulkier arginine would likely destabilize helix formation through steric hindrance (Figure 2—figure supplement 5). These data provide support for a functional model of the pathogenicity of COL27A1.G697R through destabilization of the triple helix, which may occur within developing spinal chords, long bones, and other tissues, resulting in the observed clinical features in homozygotes. We note that many other collagen disorders, including Ehlers-Danlos syndrome (McGrory et al., 1996; Tromp et al., 1995; Anderson et al., 1997), Alport syndrome (Knebelmann et al., 1992; Zhou et al., 1992) and Osteogenesis Imperfecta (Starman et al., 1989; Shapiro et al., 1992), are driven by molecular alterations of a glycine in the triple helix of the underlying collagen genes. However, all of these disorders are inherited under an autosomal dominant mode, in contrast to Steel syndrome, which has only been reported as a recessive disease. This analysis raises the question of whether some and/or milder clinical features of Steel syndrome may be present in carriers.

Assessing the health records of COL27A1.pG697R carriers reveals evidence of musculoskeletal disease

To test for clinical features of Steel syndrome in COL27A1.pG697R carriers, we performed two analyses using EHR data. The first was a test for associated medical billing codes (ICD9s) with COL27A1.pG697R carrier status, or Phenome-Wide Association Study (PheWAS) (Denny et al., 2010; Denny et al., 2013). PheWAS analysis is often performed using a general linear model (GLM), however standard implementations often do not account for scenarios where there is a large imbalance between per-test number of cases and controls, rare variants/ICD9s or the presence of elevated distant relatedness. Therefore, in addition to the GLM, we also ran three other score based tests; (i) that use saddlepoint approximation (SPATest) (Dey et al., 2017) to account for case:control imbalance; (ii) a linear mixed model (GCTA) (Yang et al., 2011) to account for distant relatedness; and (iii) a test that incorporates a bias-reduction for small numbers of observations (Firth test) (Wang, 2014). Each test was run using ICD9 codes in all individuals of Puerto Rican ancestry (N = 106 COL27A1.pG697R carriers and N = 4480 non-carriers). The five homozygotes were excluded. The ICD9 code was set as the outcome variable and COL27A1.pG697R as the primary predictor variable, including age, sex and the first five PCAs as covariates in all tests. To avoid spurious associations, we restricted the analysis to diagnosis codes with at least 3 observations (n = 367 ICD9 codes) amongst carriers.

Results of the GLM test are shown in Figure 3 and Table 2. Of the five significantly associated ICD9 codes (False Discovery Rate (FDR) < 0.05), three involved the musculoskeletal system 730.08 (pGLM < 7.1 × 10−6; odds ratio (OR) = 34.5; 95% Confidence Interval (CI) = 7.4–162), 721.0 (pGLM < 6.6 × 10−5; OR = 5.4; CI = 2.4–12.3), and 716.98 (pGLM < 4.4 × 10−4; OR = 5.8; CI = 2.2–15.3). ICD9 730.08 encodes for ‘acute osteomyelitis, other specified sites’. Manual review of chart records for these patients revealed that this code referred to vertebral osteomyelitis in the three carriers with the ICD9 code. ICD9 721.0 encodes for cervical spondylosis without myelopathy. Cervical spondylosis refers to degenerative changes of the cervical spine, which can eventually progress to encroach on the cervical canal, causing myelopathy (spinal cord injury). A third diagnosis code, 716.98, encodes for ‘arthropathy, unspecified, or involving other specified sites’. Manual review of chart records for these patients revealed that this code referred to knee arthropathy in all four patients. Finally, two other ICD9 codes were significantly associated with the COL27A1.pG697R variant; 622.10 (pGLM < 1 × 10−4; OR = 5.4; CI = 2.3–12.6), which encodes for cervical dysplasia, and 789.1 (pGLM < 2.1 × 10−4; OR = 11.6; CI = 3.2–42.2), which encodes for hepatomegaly. Presently, it is unclear whether these two are related to a COL27A1.pG697R carrier phenotype, or are spurious associations.

Figure 3 with 1 supplement see all
Download asset Open asset
Phenome-Wide Association Study (PheWAS) of COL27A1.pG697R carriers vs ICD9 billing codes derived from the Electronic Health Records (EHR) under a general linear model (GLM).

Five billing codes achieve significance (FDR adjusted p<0.05). Three of the five significant ICD9 codes are in category of musculoskeletal disorders.

https://doi.org/10.7554/eLife.25060.017
Table 2
Top five significantly PheWAS associated ICD9 codes in COL27A1.pG697R carriers (N = 106) compared to non-carriers (N = 4480).
https://doi.org/10.7554/eLife.25060.019
Disease categoryICD9 code
Short description		Number of diagnoses among carriers
N (%)		Number of diagnoses among non-carriers
N (%)		Odds ratio
(5% confidence intervals)		P-value
Neoplasms622.10Dysplasia of cervix, not otherwise specified6 (5.7)62 (1.4)5.4 (2.3–12.6)1.0 × 10–4
Musculoskeletal716.98Arthropathy unspecified, involving other unspecified sites4 (3.8)48 (1.1)5.8 (2.2–15.3)4.4 × 10–4
Musculoskeletal721.00Cervical spondylosis without myelopathy5 (4.5)74 (1.6)5.4 (2.4–12.3)6.6 × 10–5
Musculoskeletal730.08Acute osteomyelitis involving other specified sites3 (2.8)6 (0.1)34.5 (7.4–162)7.1 × 10–6
Digestive789.10Hepatomegaly3 (2.8)17 (0.4)11.6 (3.2–42.2)2.1 × 10–4

We observed over inflation in the distribution of the PheWAS test statistic, measured by lambda (λ), for all four score based models (λGLM=1.59; λSPATest=1.20; λGCTA=1.36; λFirth=2.09), indicating that no single model fully accounts for the confounding effects of distant relatedness, case:control imbalance and rare variants/ICD9s (Figure 3—figure supplement 1). The code linked to vertebral osteomyelitis (730.08) was the top signal in all tests (pSPATest < 1.4 × 10−4; pGCTA < 7.9 × 10−10; pFirth < 1.5 × 10−9), but only remains significant after genomic control adjustment in one of the tests (pGCTA_adjusted < 4.6 x 10−5). Neither codes linked to cervical spondylosis (721.0; pSPATest < 3.0 × 10−3 (rank=3rd); pGCTA < 3.3 × 10−3 (8th)) or knee arthropathy (716.98; pSPATest < 0.022 (21st); pGCTA < 3.5 × 10−3 (9th); pFirth < 0.001 (35th))) were significant after genomic control correction. Therefore, while PheWAS analysis provided preliminary support of Steel syndrome-associated clinical features in carriers, best practices for PheWAS models for rare variants/ICD9 codes, and in the presence of population structure, remains an open problem for the genomics community. It is also possible that some relevant clinical features of Steel syndrome might be poorly captured by or absent from medical billing codes.

To evaluate the preliminary evidence from the PheWAS analysis, we performed a second analysis of EHR data that focused on a comprehensive manual chart review to examine for evidence of Steel syndrome characteristics in the COL27A1.pG697R carriers in the same manner as performed for homozygotes. We limited the analysis to carriers below the age of 55 (N = 34; mean age 41.8 years) to reduce confounding from age-related related symptoms of spine and joint pain. We also selected 31 age and sex matched Puerto Rican non-carriers for comparison (mean age 40.6 years). Utilizing the same criteria used to characterize Steel syndrome cases, we found no evidence of clinical short stature or hip dislocation in carriers, but did observe a trend of elevated rates of major joint and spine degradation (Table 1). In general, 38% (13/34) of carriers showed evidence of spine degeneration varied from severe (multiple level cord compression and neurological symptoms necessitating corrective surgery) to moderate (lower back pain with no neurological symptoms managed with physical therapy and/or pain medication) compared to 13% (4/31) of non-carriers (Fishers exact test p<0.03). Specifically, we found an increased risk of cervical stenosis in 15% (5/34) of carriers compared to 0% (0/31) of controls (p<0.05). Although not reaching statistically significance, we show a trend of 2-fold higher rates of scoliosis (24%; p<0.35), arthritis (38%; p<0.1), and lumbar spine degradation (29%; p<0.25) in carriers compared to non-carriers and previous published reports in similar age groups (Kebaish et al., 2011; Reginster, 2002). Together these data suggest an appreciable burden of joint and spine degradation in COL27A1.pG697R carriers (Table 1).

Worldwide frequency and demographic history of COL27A1.pG69R

Having genetically identified and clinically characterized a previously little-known disease variant, we next investigated which populations were at risk for harboring the allele. We assessed the carrier frequencies of the COL27A1.pG697R variant in global panel of 51745 individuals from Africa (N = 376), the Americas (N = 45685), Asia (N = 5311), Europe (N = 209), the Middle East (N = 163) and Oceania (N = 28) genotyped on MEGA in the PAGE Study. This included; 13050 in the Multi-Ethnic Cohort (MEC) (Kolonel et al., 2000) Study; 12327 in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) (Lavange et al., 2010); 12852 in the Women’s Health Initiative (WHI) Study (The Women's Health Initiative Study Group, 1998); 13044 additional BioMe biobank participants (including the 1775 Puerto Ricans on MEGA described above); and a Global Reference Panel from Stanford University including the Human Genome Diversity Panel (Cann, 2002) (N = 986, see Materials and methods). Combined, the PAGE and BioMe dataset represented 57316 individuals from 112 global populations (Supplementary file 4). The COL27A1.pG697R C allele was present in 183 copies (173 heterozygous carriers and 5 homozygous cases). We estimate the carrier rate of COL27A1.G697R to be 1:51 in Puerto Rican-born individuals (minor allele frequency (MAF) = 1.1%); 1:9 in individuals born on the island of St. Thomas (MAF = 11%); 1:346 in Hispanic/Latino/as in the US (MAF = 0.29%) and 1:72 in BioMe Hispanic/Latino/a populations from New York City (MAF = 0.7%); and 1:746 in individuals born in the Dominican Republic (MAF = 0.067%) (Figure 4A). We note that only 9 people were assayed from St. Thomas, so the high carrier frequency estimate could be biased by small sample size. Finally, the variant is present in only 4 copies in the 60,706 exomes in the ExAC database (Exome Aggregation Consortium et al., 2016), likely due to differences in the populations comprising both datasets.

Figure 4 with 2 supplements see all
Download asset Open asset
Allele frequency distribution and demographic history of COL27A1.pG697R. 

(A) Global carrier frequency of COL27A1.pG697R in a multi-ethnic database of over 57,000 individuals representing 112 populations. The variant is absent or very rare in most populations (purple), at 1:746 and 1:346 carrier frequency amongst individuals from the Dominican Republic and Hispanic/Latino/as in the United States (green), and at 1:51 and 1:9 carrier frequency amongst individuals from Puerto Rico and St. Thomas (yellow). (B) Joint analysis of identity-by-descent and local ancestry haplotypes in three individuals homozygous for the COL27A1.pG697R variant. A large 15 cM interval on chromosome 9 is shown with local ancestry inferred as African (blue), European (red) and Native American (green), with shading to indicating the boundaries of the IBD haplotypes. The location of COL27A1 is indicated by the dashed line (C) Effective population size of the Puerto Rican discovery population (N = 2816) over the past 4–25 generations inferred from the tract length distribution of IBD haplotypes suggests that the ancestral population underwent a bottleneck approximately 9–14 generations ago. 95% confidence intervals are represented by blue ribbon.

https://doi.org/10.7554/eLife.25060.020

To predict what other populations might be at risk for Steel syndrome, we explored the locus-specific demographic history in carriers of the COL27A1.pG697R risk haplotype. First, by visual inspection, we were able to discriminate a single haplotype of 107.5 kb in length that contained 55 SNPs, which uniquely tagged the COL27A1.pG697R variant (R2 = 1). This haplotype was present only in individuals born in Puerto Rico (N = 25), the Dominican Republic, (N = 2), Columbia (N = 1), New York City (N = 40) and St. Thomas (N = 1). Genotyping determined that only the haplotype carriers from Puerto Rico, New York City and St. Thomas also carried the COL27A1.pG697R variant (N = 56 in total). Second, we inferred continental ancestry along the genomes of the three Puerto Rican homozygotes in the discovery cohort. Local ancestry inference is the task of assigning continental ancestry to genomic segments in an individual with recent ancestors from multiple continents. For the Puerto Rican homozygotes, we estimated local haplotypic similarity with a reference panel of African, European and Native American genomes using RFMix (Maples et al., 2013). Examination of local ancestry on the background of the IBD haplotype in all three homozygous individuals revealed all to be homozygous for Native American ancestry, suggesting the COL27A1.pG697R arose on a Native American haplotype (Figure 4B).

To test whether the disease variant arose via genetic drift or selection, we used the IBDNe software (Browning and Browning, 2015) to estimate the historical effective population size (Ne) of the Puerto Rican discovery cohort (N = 2816) (Figure 4C). The IBDNe software calculates the effective population size of a given population over past generations by modeling the distribution of IBD tract lengths present in the contemporary population. The analysis suggested evidence of a strong bottleneck in Puerto Ricans approximately 9–14 generations ago, with the smallest effective population sized dating approximately 12 generations ago (estimated Ne = 2580, 95% C.I 2320–2910). This is consistent with the timing of European immigration and slave trading on the Island, resulting in admixture and population bottlenecking, followed by demographic growth post-contact (Moreno-Estrada et al., 2013; Gravel et al., 2013). Finally, to see if there was evidence that the locus had undergone a recent selective sweep we calculated the integrated haplotype score (iHS) (Voight et al., 2006; Szpiech and Hernandez, 2014) across chromosome 9 in phased genotype data for BioMe Puerto Rican samples, but did not observe evidence of selection at the locus (Figure 4—figure supplement 1). Together, this evidence suggests that the COL27A1.pG697R variant arose in the ancestral Native American populations that peopled the Caribbean, which underwent a strong bottleneck during the period of colonization, which may help explain the prevalence of this disease in amongst contemporary Puerto Rican populations.

Discussion

Here we describe a new approach to utilize genomic data in health systems for identifying and characterizing genetic disorders, the cornerstone of which is the ability to identify related individuals in the absence of recorded pedigree or genealogy information. By linking medical records of distantly related patients, identified by shared tracts of genetic homology identical-by-descent (IBD), we discovered a recessive haplotype on 9q32 conferring extreme short stature. Whole genome sequencing revealed that a mutation (Gly697Arg) in the COL27A1 gene had been previously implicated as the genetic variant underlying Steel syndrome (Gonzaga-Jauregui et al., 2015; Steel et al., 1993; Flynn et al., 2010). Population screening indicated that the disease variant is more common than previously thought in people with Puerto Rican ancestry, and in some other Caribbean populations, and very rare or absent elsewhere in the world. Extensive analysis of clinical records confirms almost all features of the recessive disorder in cases, and reveals potential complications that can occur later in life. An agnostic survey of the medical records of carriers, supplemented by manual chart review, indicates evidence of joint and spine degradation in heterozygotes. Biochemical modeling suggests that COL27A1.G697R disrupts a conserved triple helix domain of the alpha-1 collagen in a mechanism similar to dominant forms of other collagen disorders (Persikov et al., 2004). Taken together, this study indicates that a single mutation in the COL27A1 gene underlies a common collagen disorder impacting up to 2% of people of Puerto Rican ancestry.

This is consistent with our finding, supported by previous work (Moreno-Estrada et al., 2013), demonstrating a founder effect in Puerto Rican populations. Despite segregating at an estimated carrier rate of 1:51, the COL27A1.pG697R variant was first described very recently (Gonzaga-Jauregui et al., 2015). This suggests that there may be other highly penetrant disease variants segregating at appreciable frequencies in Puerto Rican populations (Anikster et al., 2001; Cornier et al., 2008; Daniels et al., 2013; Al-Zaidy et al., 2015; Arnold et al., 2013; Lee et al., 2014), and other understudied founder populations, the discovery of which could lead to new disease variants and biology. Indeed, although COL27A1 was first implicated as the Steel syndrome disease locus in an extended family from Puerto Rico recently (Chang et al., 2015), other variants in COL27A1 have since been linked to Steel syndrome in Indian (Kotabagi et al., 2017) and Emerati (Gariballa et al., 2017) families revealing additional clinical features of the disease such as hearing loss. In our own health system, approximately 190,000 patients of Puerto Rican descent are treated annually (Humes et al., 2011). We estimate that up to 80 may have the severe homozygous form of the disorder and that the milder heterozygous form could be found in up to 1200 patients. A search of progress notes, discharge summaries, and operative reports of over 4 million patients in the Mount Sinai data warehouse discovered mentions of the text term ‘Steel Syndrome’ in 42 patient records. However, all of these patients were on dialysis for end stage renal disease, indicating that this mention was a misspelling of vascular Steal Syndrome, which is common in dialysis patients. This suggests that Steel syndrome might be largely undiagnosed. Attempts are currently being made to re-contact BioMe participants with suspected Steel syndrome, and a genetic test is now available at Mount Sinai (website: http://sema4genomics.com/products/test-catalog/).

This study highlights the benefits of incorporating statistical and population genetics approaches in medical genetic research. First, we demonstrated that leveraging distant relationships via IBD mapping was better powered for discovery of the COL27A1 variant compared to a more typical GWAS approach (i.e. genotype, imputation, and SNP association). As sample sizes increase in health systems and biobanks, the odds of a new individual being a direct or distant relative of someone already in the database increases exponentially (Henn et al., 2012), enabling the detection of shared haplotypes harboring rarer causal variants and better-powered IBD mapping studies. Second, we inferred that COL27A1.pG697R variant arose on a Native American haplotype, and we estimate that the allele may have segregated at a carrier frequency of 25–30% in pre-Columbian Taíno populations and/or been driven to its current frequency by a bottleneck that occurred during the early days of colonization in Puerto Rico. Therefore this study not only helps estimate population attributable risk of COL27A1.pG697R in Puerto Rican populations, but also to predict other populations potentially at risk, including other Caribbean and Taíno populations. Targeted population screening of COL27A1.pG697R could potentially provide personalized health management, surveillance for associated complications, guidelines for intervention (particularly in newborns [Flynn et al., 2010]), and improved reproductive choices.

This work also highlights some of the current challenges in the emerging field of genomic medicine. We demonstrated that evidence from EHRs could be readily extracted and retrospectively used to characterize clinical features of a musculoskeletal genetic disorder. However, features of many other genetic disorders may not be detectable via routine clinical exam, lab tests and radiologics, and may not be amenable to such an approach. Furthermore, statistical methods for population-scale disease variant discovery, which were predominantly developed for cohorts collected for genetic research, may not be optimally calibrated for discovery in patient populations encountered in health systems. Finally, many genetic disorders are very rare, or have more complex genetic underpinnings, which would reduce power for detection using the strategy we have described. However, recent efforts, such as the Precision Medicine Initiative, that focus on the broad adoption of genomics in medicine, combined with international efforts to catalog rare genetic diseases, are primed to increase the rate of incidental genetic diagnosis of disease.

In summary, this work demonstrates the utility of biobanks for exploring full medical phenomes, and highlights the importance of documenting a wider spectrum of genetic disorders, in large and diverse populations of humans. In particular, this method provides a bridge between classical medical genetic methods and those employed in population-level GWAS. Here we note that the COL27A1 variant is very rare in current large-scale genomic databases used for clinical research. Thus traditional association strategies and ascertainment bias focused on populations of European descent would have failed to identify and characterize this disorder and its public health burden. As ours and other recent studies have demonstrated, EHR-embedded research will be increasingly important for disentangling the pathology of rare genetic disorders, and understanding the continuum of complex and Mendelian disease. As studies grow in size, and healthcare systems learn to leverage the wealth of information captured in the EHR, there is a need to provide relevant medical information to any patient entering the clinic anywhere in the world. Methods like that described here allow for precision medicine with a truly global outlook.

Materials and methods

BioMe biobank program

Request a detailed protocol

Study participants were recruited from the BioMe Biobank Program of The Charles Bronfman Institute for Personalized Medicine at Mount Sinai Medical Center from 2007 onward. The BioMe Biobank Program (Institutional Review Board 07–0529) operates under a Mount Sinai Institutional Review Board-approved research protocol. All study participants provided written informed consent. Of the approximately 38000 participants currently enrolled in BioMe, N = 10511 unrelated are genotyped on the Illumina Infinium OmniExpress (OMNI) array. 5102 of these participants self-report as ‘Hispanic or Latino/a’, 3080 as ‘African American or African’, 2078 as ‘White or Caucasian’, 89 as ‘Mixed’ and 162 as ‘Other’. Country of origin information is available for all but N = 5 participants, with N = 6553 reporting being born in the United States and the remaining N = 3953 report being born outside of the US. Parental and grandparental country of origin information is only available for a small subset of individuals genotyped on the OMNI array (N = 43). An additional N = 10471 participants were genotyped on the Illumina Infinium Multi Ethnic Genotyping array (MEGA) v1.0. Of these, approximately 4704 self-reported ‘Hispanic or Latino/a’ ethnicity, 3143 self-reported as ‘African American or African’, 22 self-reported as ‘White/Caucasian’, 708 self-reported as ‘Mixed’ and 1894 self-reported as ‘Other’. Country of birth information was available for all but a small number of participants (N = 228), with 5190 reporting being born in the United States, and the remaining 5053 self-reporting being born elsewhere. Parental and grandparental country of origin information is available for 4323 individuals genotyped on the MEGA array.

OmniExpress genotyping and QC

Request a detailed protocol

Genotyping of 12749 BioMe participants was performed on the Illumina Infinium OmniExpress plus HumanExome array. Calling was performed using the GenomeStudio software. A total of 1093 individuals were removed prior to zCall due to plate failure (N = 672), unambiguous discordance between genetic and EHR recorded sex (N = 693), a call rate of <98% (N = 834), or deviances in levels of heterozygosity (N = 773 in total). This was defined as having either an inbreeding coefficient outside the range −0.1 and 0.3 for common alleles (MAF >1%), or between 0.4 and 0.9 for rare alleles (MAF <1%). Additional quality control of 11656 individuals was performed using PLINK1.7 (Purcell et al., 2007) (RRID:SCR_001757). An individual with a call rate of <99% was also excluded (N = 1), along with intentional genetic duplicates (PiHat >0.8, N = 444). Site-level quality control consisted of the removal of SNPs with a call rate of <95% (n = 42217), and the removal of sites that were significantly out of Hardy-Weinberg equilibrium (p<1×10−5; n = 39660) when calculated for self-reported EA, AA and H/L separately. Palindromic sites and those that deviated considerably from the 1KGP allele frequencies (<40% versus >60%) were also removed to ensure uniform stranding across datasets. After QC steps, 11212 participants and 866864 SNPs remained for downstream analysis.

IBS relatedness estimates and estimation of inbreeding Co-efficient

Request a detailed protocol

Pairwise IBS-based relationship estimates were derived for BioMe participants (N = 11212) using the RELATEAdmix software (Moltke and Albrechtsen, 2014), which accounts for inflation of IBS statistic due to admixture linkage disequillibrium in admixed populations. To include allele frequency information and global ancestry proportions from ancestral populations relevant for each admixed population in the analysis. These were estimated using ADMIXTURE (Alexander et al., 2009) (RRID:SCR_001263) H/L samples were merged with the Utah Residents (CEPH) with Northern and Western European Ancestry (CEU; N = 100), Yoruba in Ibadan, Nigeria (YRI; N = 100) and Native American (NA; N = 43; including Nauha, Ayamaran, Mayan and Quechan individuals) and used as input for the ADMIXTURE software, which was run unsupervised at k = 3. ADMIXTURE analysis confirmed that NA reference panel comprised >99% proportion Native American genetic ancestry (Figure 4—figure supplement 2). European-American (EA) individuals were merged with the CEU and a panel of self-reported Ashkenazi Jewish individuals genotyped on OMNI from BioMe (AJ; N = 100) and run unsupervised at k = 2. AA samples were merged with the CEU and YRI reference panels and run unsupervised at k = 2. After intersecting with reference panels 99296 SNPs were used as the input for RELATEAdmix.

Principal component analysis

Request a detailed protocol

Principal Component Analysis (PCA) was performed using the SMARTPCAv10210 software from the EIGENSOFTv5.0.1 (RRID:SCR_004965) (Price et al., 2006) in 10511 unrelated BioMe participants. Regions containing the Human Leukocyte Antigen (chr6: 27000000–35000000 (NCBI37/hg19)), Lactase gene (chr2:135000000–137000000 (NCBI37/hg19)) and a common inversion (chr8:6000000–16000000 (NCBI37/hg19)), all of which are regions known to confound PCA analysis were removed from the genotype data prior to analysis. Data were merged with a reference panel of 2504 individuals from Phase 3 of the 1KGP (RRID:SCR_006828) (The 1000 Genomes Project Consortium, 2015) that was constructed by extracting OmniExpress sites from whole-genome sequence data. Following this, a further two other relevant reference panels were added: the NA (N = 43), and AJ (N = 100) panels described above. A total of 174468 SNPs remained after intersecting the data with these reference panels.

Identity-by-descent tract inference and clustering

Request a detailed protocol

Phased genotype data were filtered to MAF >0.01 and converted to PLINK format using the FCGENE software (Roshyara and Scholz, 2014) (we avoided using PLINK software for the conversion process in order to retain the phase information). Recombination maps from HapMap II (Build GRCh37/hg19) were intersected with the genotyped sites (n = 490510 SNPs). GERMLINE (RRID:SCR_001720) (Gusev et al., 2009) was used to infer tracts of identity by descent >3 cM across all pairs of BioMe individuals (N = 11212) using the following flags: ‘-min_m 3 -err_hom 0 -err_het 2 -bits 25 –haploid’. IBD haplotypes that fell within or overlapped with centromeres, telomeres and regions of low complexity were removed from the GERMLINE output using an in-house Ruby script. Additional quality control measures consisted of the exclusion of regions of the genome where the depth of IBD-sharing (that is, the number of pairwise IBD-haplotypes that contain a given locus of the genome) exceeded 4 standard deviations from the genome-wide mean (Figure 2—figure supplement 6).

IBD clustering to identify ‘cliques' of three or more IBD haplotypes shared between multiple individuals was then performed using the efficient connect-component-based clustering version of the Dash Associated Shared Haplotypes algorithm (DASH) (Gusev et al., 2011), using the default parameters. As a further quality control measure IBD-sharing ‘cliques’ inferred by DASH that exhibited excessive sharing (which we defined as clique membership that exceeded 4 s.d. above the genome-wide mean) were removed (Figure 2—figure supplement 7). Data was outputted from DASH in PLINK tped format, and alleles were encoded as; homozygote member in a clique as ‘2’, heterozygote member as ‘1’ and everyone else not a member in the clique encoded as ‘0’.

Population-level IBD sharing

Request a detailed protocol

We calculated the length of any pairwise IBD tract (or sum of the lengths if a pair of individuals shared more than one tract IBD) for each IBD sharing pair within each population to obtain an estimate of the mean and variance of pairwise sharing per population. To compare the tract length distribution between populations (of size N), we first binned pairwise IBD tracts by length bin in 0.01 cM increments. We then summed the number of pairwise IBD tracts falling into each length bin (x), and divided this number by the number of possible pairwise IBD sharing for each population: N*(N-1)/2.

Height measurement and transformation

Request a detailed protocol

A self-reported measurement of height in feet and inches was recorded for each participant at enrollment into the BioMe program. Raw height data were stratified on the basis of sex for all individuals who were inferred to be of Puerto Rican ancestry (N = 2816). Height data was then log transformed and converted to age-adjusted Z-scores. Participants were excluded on the basis of age reported at the point of enrollment, with a minimum cut-off of 18 years old for females (N = 0) and 22 for males (N = 0), and a maximum cut off of 79 years old for both sexes (N = 194) leaving a total of n = 2622 PR.

Association of IBD-cliques with height under a recessive model

Request a detailed protocol

Association of IBD clique membership with height as a continuous trait was performed under a recessive model using PLINKv1.9 (Chang et al., 2015) using the ‘--linear recessive’ flag. Age and sex adjusted Z-scores for height were used as the outcome variable. IBD clique membership was used as the primary predictor variable and the first five PCA eigenvectors were used as covariates. The model was run across a total of 2622 PR ancestry individuals and a total of 480 IBD-cliques where at least 3 individuals were homozygous for the IBD haplotype.

Genome wide association of imputed data under a recessive model

Request a detailed protocol

Genotype data for all of the BioMe individuals ascertained on the Illumina OMNI Express array (N = 11212) were phased together using SHAPEIT2 (Delaneau et al., 2011; O'Connell et al., 2014). Imputation was subsequently performed in 5 MB chunks using IMPUTE2 (RRID:SCR_013055) (Howie et al., 2009)via the flags ‘-Ne 20000 -buffer 250 -filt_rules_l 'ALL<0.0002' 'ALL>0.9998'’ with a reference panel derived from phase 3 data from the 1KGP. A total of 46538253 SNPs were imputed from 828109 directly genotyped SNPs.

We ran a recessive GWAS on the same 2622 inferred Puerto Rican ancestry individuals used in our recessive IBD-mapping model. The association was run over hard-called data using the PLINKv1.9 software using the ‘--linear recessive’ flag. Age and sex adjusted Z-scores for height were used as the phenotypic outcome and the first five PC eigenvectors were used as covariates. Analysis was restricted to SNPs with >= 2 observations of individuals homozygous for the minor allele (as the only 2 of the 3 homozygotes had been imputed correctly), and SNPs with an INFO score of >= 0.3 (n = 10007795 SNPs in total).

Whole genome sequencing

Request a detailed protocol

Genomic libraries were prepared from DNA obtained for the four IBD homozygous individuals. DNA was sheared to 300 bp on a Covaris E220, libraries were made using the NEBNext Ultra DNA Library Prep kit for Illumina. The libraries were submitted for Whole Genome Sequencing (WGS) at the Mount Sinai Genomic Core using the Illumina HiSeq 2500 system, performed by the Genomics Core Facility of the Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai. Reads were aligned to the NCBI37/hg19 reference genome and variants were called using the sequence analysis pipeline by Linderman et al. (2014) Variant calls and coverage at every site at the genomic interval spanned by the candidate IBD haplotype (chr9:112000000–118000000 bp (NCBI37/hg19)) were obtained using the ‘-out_mode EMIT_ALL_SITES’ flag in GATKv3.2–72 (RRID:SCR_001876). For summary statistics of whole genome sequencing (WGS) see Supplement file 1.

In silico analysis and validation of COL27A1.pG967R

Request a detailed protocol

WGS variant calls were annotated with allele frequency information and in silico prediction scores for SIFT, PhyloP, GERP generated using snpEffv3.0 (RRID:SCR_005191) as part of the sequence analysis pipeline published by Linderman et al. (2014). We identified all genomic variants that were present in at least 6 copies across the four IBD-homozygotes and that lay within the shared boundary of the IBD haplotype. Using this criteria, only one rare, coding variant was found to be shared between all four homozygotes, namely a point mutation in the gene COL27A1 (g.9:116958257 .C>G, NM_032888.1, p.G697R, rs140950220) which was present in 7 copies (with 3 individuals being homozygous, and the fourth being heterozygous). The rs140950220 G/C allele status was validated by Sanger sequencing of exon 7 in the COL27A1 gene in all four individuals. We also validated COL27A1.pG697R status in individuals carrying the significant IBD-clique at 9q32 using the Fluidigm SNPType assay adhering to the standard protocol. All individuals carrying at least one copy of the top IBD-haplotype (N = 59) were genotyped for the rs140950220 variant in addition to a panel of age and sex matched Puerto Rican ancestry controls (N = 59).

Genotyping COL27A1.pG697R in a Multi-Ethnic population of PAGE

Request a detailed protocol

We estimated the frequency of the COL27A1.pG697R (dbSNP = rs140950220) variant in the Population Architecture using Genomics and Epidemiology (PAGE) study. The PAGE study comprises a diverse global reference panel from five studies. African-American and Hispanic/Latina women from the Women’s Health Initiative (WHI), a multi-center cohort study investigating post-menopausal women’s health in the US and recruited women at 40 centers across the US. Self-identified Hispanic/Latino/as from four sites in San Diego, CA, Chicago, IL, Bronx, NY, and Miami, FL as part of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). African American, Japanese American, and Native Hawaiian participants from the Multiethnic Cohort (MEC) prospective cohort study recruiting men and women from Hawaii and California. The Global Reference Panel (GRP) created by Stanford University contributed samples including; a population sample of Andean individuals primarily of Quechuan/Aymaran ancestry from Puno, Peru; a population sample of Easter Island (Rapa Nui), Chile; individuals of indigenous origin from Oaxaca, Mexico, Honduras, Colombia, the Nama and Khomani KhoeSan populations of the Northern Cape, South Africa; the Human Genome Diversity Panel in collaboration with the Centre Etude Polymorphism Humain (CEPH) in Paris; and the Maasai in Kinyawa, Kenya (MKK) dataset from the International Hapmap Project hosted at Coriell. Finally, the BioMe biobank in the Mount Sinai health system, New York City, contributed African-American, Hispanic/Latino/a, and participants who reported as mixed or other ancestry to the PAGE study,~50% of whom were born outside New York City and for whom country-of-birth information was available. In all, participants in the PAGE Study represent a global reference panel of 112 populations ranging from 4 to 17773 individuals in size (Supplement file 4). Samples in the PAGE study were genotyped on the Illumina Multi-Ethnic Genotyping Array (MEGA), which included direct genotyping of the rs140950220 variant. A total of 53338 PAGE and GRP samples were genotyped on the MEGA array at the Johns Hopkins Center for Inherited Disease Research (CIDR), with 52878 samples successfully passing CIDR’s QC process. Genotyping data that passed initial quality control at CIDR were released to the Quality Assurance/Quality Control (QA/QC) analysis team at the University of Washington Genetics Coordinating Center (UWGCC). The UWGCC further cleaned the data according to previously described methods (Laurie et al., 2010) and returned genotypes for 51520 subjects. A total of 1705969 SNPs were genotyped on the MEGA. The COL27A1.pG697R variant passed the following filters; (1) CIDR technical filters, (2) SNPs with missing call rate >= 2%, (3) SNPs with more than 6 discordant calls in 988 study duplicates, (4) SNPs with greater than 1 Mendelian errors in 282 trios and 1439 duos, (5) SNPs with a Hardy-Weinberg p<10−10, (6) positional duplicates.

Structural modeling of the COL27A1.PG697R missense variant

Request a detailed protocol

We downloaded X-ray crystal coordinates (1CAG from Bella et al., 1994.; www.pdb.org) on January 21, 2017. Visualization and modeling of the missense variant were performed in PyMol (www.pymol.org; RRID:SCR_000305).

Phenome-Wide association study

Request a detailed protocol

To test for clinical symptoms of Steel syndrome in COL27A1.pG967R carriers, we performed a Phenome-Wide Association Study (PheWas) with EHR-derived ICD9 billing codes as the phenotypic outcome. In the association model, for each individual ICD9 codes were encoded as ‘1’ if the ICD9 was present in their EHR, and ‘0’ if the ICD9 code was absent. Carrier status for COL27A1.pG697R was used as the primary predictor variable, with heterozygous individuals encoded as ‘1’, non-carriers encoded a ‘0’ and homozygotes excluded from the analysis. We restricted the analysis to carriers of COL27A1.pG697R (n = 106) and non-carriers (n = 4480) who either reported being born in Puerto Rico or who were US-born, self-identified as H/L and overlapped with Puerto Rican born individuals in principal component analysis. Age, sex and the first 5 principal components were included as covariates in our model. The regression was performed using four methods; Generalized Linear Models (GLM) using the glm() function in Rv3.2.1; a score test based on the saddlepoint approximation (SPATest) using the SPAtest() function in Rv3.2.1; a score test using a base adjustment for rare variants (Firth test) using the logistf() function in Rv3.2.1; and a linear mixed model using the GCTAv1.24.2 software with a genetic relationship matrix constructed from 281666 SNPs shared between the OMNI and MEGA arrays (MAF >= 1%). To adjust for multiple tests, raw p-values were adjusted for false discovery rate using the p.adjust() function in R, and only those below an FDR adjusted p-value of 0.05 were reported as significant.

Clinical review of patient records

Request a detailed protocol

Information from inpatient, outpatient, emergency and private practice settings housed in the Mount Sinai health system since 2004 was reviewed by two clinical experts independently. This data includes laboratory reports, radiological data, pathology results, operative and inpatient/outpatient progress notes, discharge summaries, pharmacy, and nurses reports. The clinical experts examined for clinical features similar to those reported for Steel syndrome cases in Flynn et al. (2010), including developmental dysplasia of the hip (or congenital hip dysplasia), carpal coalition, scoliosis, and joint and spine anomalies. Both clinical experts reviews patient records independently and compared notes to resolve discrepancies. They reviewed the records of the 34 youngest COL27A1.pG697R carriers (mean age 42), and compared their findings to 31 randomly selected age and sex matched Puerto Rican non-carriers, and also to published reports of population prevalences of key clinical features for similar age groups where available.

Local ancestry estimation

Request a detailed protocol

Due to the process of recombination, individuals from populations that have undergone recent admixture can exhibit a mosaic of genetic ancestry along their genome. Their genetic ancestry at a given genomic segment (referred to as local ancestry), can be inferred from genotype data with the use of non-admixed reference panels of known continental ancestry. We calculated local ancestry in the three homozygous Puerto Rican individuals genotyped on OMNI by first extracting the intersecting sites of the Affymetrix 6.0 array (n = 593729 SNPs in total) and merging them with 3 ancestral reference panels. These reference panels consisted of the CEU and YRI samples from the 1KGP in addition to the Native American reference panel described previously that were used as a proxy for European, African and Native American ancestral source populations, respectively. RFMix (Maples et al., 2013) was used to infer local ancestry.

Calculation of historical effective population size in Puerto Ricans

Request a detailed protocol

To investigate evidence of a founder effect in Puerto Ricans we ran the IBDNe software (Browning and Browning, 2015) in 2816 Puerto Ricans from the discovery effort using the cleaned set of pairwise IBD-haplotypes inferred using GERMLINE. IBDNe was run using the default parameters, including an assumed generation time of 25 years.

Data availability

Request a detailed protocol

All scripts used to generate main and supplementary figures for this manuscript are available for download on GitHub (https://github.com/gillian-belbin/ibdmapping_ehr_figscripts [Belbin, 2017]; a copy is archived at https://github.com/elifesciences-publications/ibdmapping_ehr_figscripts). The data frames of analysis results that were used to generate the main and supplementary figures are located here: http://research.mssm.edu/kennylab/data_source_file.tar.gz

Web resources

Request a detailed protocol

BioMe OmniExpress data: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000888.v1.p1

BioMe MEGA data: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000925

PAGE MEGA data: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356

Location of Native American panels: ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130711_native_american_admix_train/

Software used in the analysis:

SMARTPCA: https://github.com/DReichLab/EIG

ADMIXTURE: https://www.genetics.ucla.edu/software/admixture/download.html

RelateAdmix: http://www.popgen.dk/software/index.php/RelateAdmix#Download

RFMix: https://sites.google.com/site/rfmixlocalancestryinference/

GERMLINE: http://www.cs.columbia.edu/~gusev/germline/

DASH: http://www1.cs.columbia.edu/~gusev/dash/

PyMol: www.pymol.org

IBDNe: http://faculty.washington.edu/browning/ibdne.html

Data availability

The following previously published data sets were used

References

    1. Green RC
    2. Goddard KAB
    3. Jarvik GP
    4. Amendola LM
    5. Appelbaum PS
    6. Berg JS
    7. Bernhardt BA
    8. Biesecker LG
    9. Biswas S
    10. Blout CL
    11. Bowling KM
    12. Brothers KB
    13. Burke W
    14. Caga-anan CF
    15. Chinnaiyan AM
    16. Chung WK
    17. Clayton EW
    18. Cooper GM
    19. East K
    20. Evans JP
    21. Fullerton SM
    22. Garraway LA
    23. Garrett JR
    24. Gray SW
    25. Henderson GE
    26. Hindorff LA
    27. Holm IA
    28. Lewis MH
    29. Hutter CM
    30. Janne PA
    31. Joffe S
    32. Kaufman D
    33. Knoppers BM
    34. Koenig BA
    35. Krantz ID
    36. Manolio TA
    37. McCullough L
    38. McEwen J
    39. McGuire A
    40. Muzny D
    41. Myers RM
    42. Nickerson DA
    43. Ou J
    44. Parsons DW
    45. Petersen GM
    46. Plon SE
    47. Rehm HL
    48. Roberts JS
    49. Robinson D
    50. Salama JS
    51. Scollon S
    52. Sharp RR
    53. Shirts B
    54. Spinner NB
    55. Tabor HK
    56. Tarczy-Hornoch P
    57. Veenstra DL
    58. Wagle N
    59. Weck K
    60. Wilfond BS
    61. Wilhelmsen K
    62. Wolf SM
    63. Wynn J
    64. Yu J-H
    65. Amaral M
    66. Amendola L
    67. Appelbaum PS
    68. Aronson SJ
    69. Arora S
    70. Azzariti DR
    71. Barsh GS
    72. Bebin EM
    73. Biesecker BB
    74. Biesecker LG
    75. Biswas S
    76. Blout CL
    77. Bowling KM
    78. Brothers KB
    79. Brown BL
    80. Burt AA
    81. Byers PH
    82. Caga-anan CF
    83. Calikoglu MG
    84. Carlson SJ
    85. Chahin N
    86. Chinnaiyan AM
    87. Christensen KD
    88. Chung W
    89. Cirino AL
    90. Clayton E
    91. Conlin LK
    92. Cooper GM
    93. Crosslin DR
    94. Davis JV
    95. Davis K
    96. Deardorff MA
    97. Devkota B
    98. De Vries R
    99. Diamond P
    100. Dorschner MO
    101. Dugan NP
    102. Dukhovny D
    103. Dulik MC
    104. East KM
    105. Rivera-Munoz EA
    106. Evans B
    107. Evans JP
    108. Everett J
    109. Exe N
    110. Fan Z
    111. Feuerman LZ
    112. Filipski K
    113. Finnila CR
    114. Fishler K
    115. Fullerton SM
    116. Ghrundmeier B
    117. Giles K
    118. Gilmore MJ
    119. Girnary ZS
    120. Goddard K
    121. Gonsalves S
    122. Gordon AS
    123. Gornick MC
    124. Grady WM
    125. Gray DE
    126. Gray SW
    127. Green R
    128. Greenwood RS
    129. Gutierrez AM
    130. Han P
    131. Hart R
    132. Heagerty P
    133. Henderson GE
    134. Hensman N
    135. Hiatt SM
    136. Himes P
    137. Hindorff LA
    138. Hisama FM
    139. Ho CY
    140. Hoffman-Andrews LB
    141. Holm IA
    142. Hong C
    143. Horike-Pyne MJ
    144. Hull S
    145. Hutter CM
    146. Jamal S
    147. Jarvik GP
    148. Jensen BC
    149. Joffe S
    150. Johnston J
    151. Karavite D
    152. Kauffman TL
    153. Kaufman D
    154. Kelley W
    155. Kim JH
    156. Kirby C
    157. Klein W
    158. Knoppers B
    159. Koenig BA
    160. Kong SW
    161. Krantz I
    162. Krier JB
    163. Lamb NE
    164. Lambert MP
    165. Le LQ
    166. Lebo MS
    167. Lee A
    168. Lee KB
    169. Lennon N
    170. Leo MC
    171. Leppig KA
    172. Lewis K
    173. Lewis M
    174. Lindeman NI
    175. Lockhart N
    176. Lonigro B
    177. Lose EJ
    178. Lupo PJ
    179. Rodriguez LL
    180. Lynch F
    181. Machini K
    182. MacRae C
    183. Manolio TA
    184. Marchuk DS
    185. Martinez JN
    186. Masino A
    187. McCullough L
    188. McEwen J
    189. McGuire A
    190. McLaughlin HM
    191. McMullen C
    192. Mieczkowski PA
    193. Miller J
    194. Miller VA
    195. Mody R
    196. Mooney SD
    197. Moore EG
    198. Morris E
    199. Murray M
    200. Muzny D
    201. Myers RM
    202. Ng D
    203. Nickerson DA
    204. Oliver NM
    205. Ou J
    206. Parsons W
    207. Patrick DL
    208. Pennington J
    209. Perry DL
    210. Petersen G
    211. Plon S
    212. Porter K
    213. Powell BC
    214. Punj S
    215. Breitkopf CR
    216. Raesz-Martinez RA
    217. Raskind WH
    218. Rehm HL
    219. Reigar DA
    220. Reiss JA
    221. Rich CA
    222. Richards CS
    223. Rini C
    224. Roberts S
    225. Robertson PD
    226. Robinson D
    227. Robinson JO
    228. Robinson ME
    229. Roche MI
    230. Romasko EJ
    231. Rosenthal EA
    232. Salama J
    233. Scarano MI
    234. Schneider J
    235. Scollon S
    236. Seidman CE
    237. Seifert BA
    238. Sharp RR
    239. Shirts BH
    240. Sholl LM
    241. Siddiqui J
    242. Silverman E
    243. Simmons S
    244. Simons JV
    245. Skinner D
    246. Spinner NB
    247. Stoffel E
    248. Strande NT
    249. Sunyaev S
    250. Sybert VP
    251. Taber J
    252. Tabor HK
    253. Tarczy-Hornoch P
    254. Taylor DM
    255. Tilley CR
    256. Tomlinson A
    257. Trinidad S
    258. Tsai E
    259. Ubel P
    260. Van Allen EM
    261. Vassy JL
    262. Vats P
    263. Veenstra DL
    264. Vetter VL
    265. Vries RD
    266. Wagle N
    267. Walser SA
    268. Walsh RC
    269. Weck K
    270. Werner-Lin A
    271. Whittle J
    272. Wilfond B
    273. Wilhelmsen KC
    274. Wolf SM
    275. Wynn J
    276. Yang Y
    277. Young C
    278. Yu J-H
    279. Zikmund-Fisher BJ
    (2016) Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine
    The American Journal of Human Genetics 98:1051–1066.
    https://doi.org/10.1016/j.ajhg.2016.04.011
    1. Humes KR
    2. Jones N
    3. Ramirez RR
    (2011)
    Overview of Race and Hispanic Origin: 2010
    Overview of Race and Hispanic Origin: 2010.
    1. Knebelmann B
    2. Deschenes G
    3. Gros F
    4. Hors MC
    5. Grünfeld JP
    6. Zhou J
    7. Tryggvason K
    8. Gubler MC
    9. Antignac C
    (1992)
    Substitution of arginine for glycine 325 in the collagen alpha 5 (IV) chain associated with X-linked Alport syndrome: characterization of the mutation by direct sequencing of PCR-amplified lymphoblast cDNA fragments
    American Journal of Human Genetics 51:135–142.
    1. Lango Allen H
    2. Estrada K
    3. Lettre G
    4. Berndt SI
    5. Weedon MN
    6. Rivadeneira F
    7. Willer CJ
    8. Jackson AU
    9. Vedantam S
    10. Raychaudhuri S
    11. Ferreira T
    12. Wood AR
    13. Weyant RJ
    14. Segrè AV
    15. Speliotes EK
    16. Wheeler E
    17. Soranzo N
    18. Park JH
    19. Yang J
    20. Gudbjartsson D
    21. Heard-Costa NL
    22. Randall JC
    23. Qi L
    24. Vernon Smith A
    25. Mägi R
    26. Pastinen T
    27. Liang L
    28. Heid IM
    29. Luan J
    30. Thorleifsson G
    31. Winkler TW
    32. Goddard ME
    33. Sin Lo K
    34. Palmer C
    35. Workalemahu T
    36. Aulchenko YS
    37. Johansson A
    38. Zillikens MC
    39. Feitosa MF
    40. Esko T
    41. Johnson T
    42. Ketkar S
    43. Kraft P
    44. Mangino M
    45. Prokopenko I
    46. Absher D
    47. Albrecht E
    48. Ernst F
    49. Glazer NL
    50. Hayward C
    51. Hottenga JJ
    52. Jacobs KB
    53. Knowles JW
    54. Kutalik Z
    55. Monda KL
    56. Polasek O
    57. Preuss M
    58. Rayner NW
    59. Robertson NR
    60. Steinthorsdottir V
    61. Tyrer JP
    62. Voight BF
    63. Wiklund F
    64. Xu J
    65. Zhao JH
    66. Nyholt DR
    67. Pellikka N
    68. Perola M
    69. Perry JR
    70. Surakka I
    71. Tammesoo ML
    72. Altmaier EL
    73. Amin N
    74. Aspelund T
    75. Bhangale T
    76. Boucher G
    77. Chasman DI
    78. Chen C
    79. Coin L
    80. Cooper MN
    81. Dixon AL
    82. Gibson Q
    83. Grundberg E
    84. Hao K
    85. Juhani Junttila M
    86. Kaplan LM
    87. Kettunen J
    88. König IR
    89. Kwan T
    90. Lawrence RW
    91. Levinson DF
    92. Lorentzon M
    93. McKnight B
    94. Morris AP
    95. Müller M
    96. Suh Ngwa J
    97. Purcell S
    98. Rafelt S
    99. Salem RM
    100. Salvi E
    101. Sanna S
    102. Shi J
    103. Sovio U
    104. Thompson JR
    105. Turchin MC
    106. Vandenput L
    107. Verlaan DJ
    108. Vitart V
    109. White CC
    110. Ziegler A
    111. Almgren P
    112. Balmforth AJ
    113. Campbell H
    114. Citterio L
    115. De Grandi A
    116. Dominiczak A
    117. Duan J
    118. Elliott P
    119. Elosua R
    120. Eriksson JG
    121. Freimer NB
    122. Geus EJ
    123. Glorioso N
    124. Haiqing S
    125. Hartikainen AL
    126. Havulinna AS
    127. Hicks AA
    128. Hui J
    129. Igl W
    130. Illig T
    131. Jula A
    132. Kajantie E
    133. Kilpeläinen TO
    134. Koiranen M
    135. Kolcic I
    136. Koskinen S
    137. Kovacs P
    138. Laitinen J
    139. Liu J
    140. Lokki ML
    141. Marusic A
    142. Maschio A
    143. Meitinger T
    144. Mulas A
    145. Paré G
    146. Parker AN
    147. Peden JF
    148. Petersmann A
    149. Pichler I
    150. Pietiläinen KH
    151. Pouta A
    152. Ridderstråle M
    153. Rotter JI
    154. Sambrook JG
    155. Sanders AR
    156. Schmidt CO
    157. Sinisalo J
    158. Smit JH
    159. Stringham HM
    160. Bragi Walters G
    161. Widen E
    162. Wild SH
    163. Willemsen G
    164. Zagato L
    165. Zgaga L
    166. Zitting P
    167. Alavere H
    168. Farrall M
    169. McArdle WL
    170. Nelis M
    171. Peters MJ
    172. Ripatti S
    173. van Meurs JB
    174. Aben KK
    175. Ardlie KG
    176. Beckmann JS
    177. Beilby JP
    178. Bergman RN
    179. Bergmann S
    180. Collins FS
    181. Cusi D
    182. den Heijer M
    183. Eiriksdottir G
    184. Gejman PV
    185. Hall AS
    186. Hamsten A
    187. Huikuri HV
    188. Iribarren C
    189. Kähönen M
    190. Kaprio J
    191. Kathiresan S
    192. Kiemeney L
    193. Kocher T
    194. Launer LJ
    195. Lehtimäki T
    196. Melander O
    197. Mosley TH
    198. Musk AW
    199. Nieminen MS
    200. O'Donnell CJ
    201. Ohlsson C
    202. Oostra B
    203. Palmer LJ
    204. Raitakari O
    205. Ridker PM
    206. Rioux JD
    207. Rissanen A
    208. Rivolta C
    209. Schunkert H
    210. Shuldiner AR
    211. Siscovick DS
    212. Stumvoll M
    213. Tönjes A
    214. Tuomilehto J
    215. van Ommen GJ
    216. Viikari J
    217. Heath AC
    218. Martin NG
    219. Montgomery GW
    220. Province MA
    221. Kayser M
    222. Arnold AM
    223. Atwood LD
    224. Boerwinkle E
    225. Chanock SJ
    226. Deloukas P
    227. Gieger C
    228. Grönberg H
    229. Hall P
    230. Hattersley AT
    231. Hengstenberg C
    232. Hoffman W
    233. Lathrop GM
    234. Salomaa V
    235. Schreiber S
    236. Uda M
    237. Waterworth D
    238. Wright AF
    239. Assimes TL
    240. Barroso I
    241. Hofman A
    242. Mohlke KL
    243. Boomsma DI
    244. Caulfield MJ
    245. Cupples LA
    246. Erdmann J
    247. Fox CS
    248. Gudnason V
    249. Gyllensten U
    250. Harris TB
    251. Hayes RB
    252. Jarvelin MR
    253. Mooser V
    254. Munroe PB
    255. Ouwehand WH
    256. Penninx BW
    257. Pramstaller PP
    258. Quertermous T
    259. Rudan I
    260. Samani NJ
    261. Spector TD
    262. Völzke H
    263. Watkins H
    264. Wilson JF
    265. Groop LC
    266. Haritunians T
    267. Hu FB
    268. Kaplan RC
    269. Metspalu A
    270. North KE
    271. Schlessinger D
    272. Wareham NJ
    273. Hunter DJ
    274. O'Connell JR
    275. Strachan DP
    276. Wichmann HE
    277. Borecki IB
    278. van Duijn CM
    279. Schadt EE
    280. Thorsteinsdottir U
    281. Peltonen L
    282. Uitterlinden AG
    283. Visscher PM
    284. Chatterjee N
    285. Loos RJ
    286. Boehnke M
    287. McCarthy MI
    288. Ingelsson E
    289. Lindgren CM
    290. Abecasis GR
    291. Stefansson K
    292. Frayling TM
    293. Hirschhorn JN
    (2010) Hundreds of variants clustered in genomic loci and biological pathways affect human height
    Nature 467:832–838.
    https://doi.org/10.1038/nature09410
    1. Reginster JY
    (2002)
    The prevalence and burden of arthritis
    Rheumatology 41 Supp 1:3–6.
    1. The Women's Health Initiative Study Group
    (1998)
    Design of the Women’s Health Initiative clinical trial and observational study
    Controlled Clinical Trials 19:61–109.
    1. Zhou J
    2. Hertz JM
    3. Tryggvason K
    (1992)
    Mutation in the alpha 5(IV) collagen chain in juvenile-onset Alport syndrome without hearing loss or ocular lesions: detection by denaturing gradient gel electrophoresis of a PCR product
    American Journal of Human Genetics 50:1291–1300.

Article and author information

Author details

  1. Gillian Morven Belbin

    1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    3. The Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Conceptualization, Data curation, Software, Formal analysis, Supervision, Visualization, Methodology, Writing—original draft, Writing—review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9036-864X

  2. Jacqueline Odgis

    Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Formal analysis, Validation, Writing—review and editing
    Competing interests
    No competing interests declared

  3. Elena P Sorokin

    Department of Genetics, Stanford University School of Medicine, Stanford, United States
    Contribution
    Formal analysis, Visualization, Writing—review and editing
    Competing interests
    No competing interests declared

  4. Muh-Ching Yee

    Department of Plant Biology, Carnegie Institution for Science, Stanford, United States
    Contribution
    Validation, Methodology, Writing—review and editing
    Competing interests
    No competing interests declared

  5. Sumita Kohli

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Formal analysis, Validation, Writing—review and editing
    Competing interests
    No competing interests declared

  6. Benjamin S Glicksberg

    1. Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    2. The Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    3. Harris Center for Precision Wellness, Icahn School of Medicine at Mt Sinai, New York, United States
    Contribution
    Formal analysis, Writing—review and editing
    Competing interests
    No competing interests declared

  7. Christopher R Gignoux

    Department of Genetics, Stanford University School of Medicine, Stanford, United States
    Contribution
    Investigation, Writing—review and editing
    Competing interests
    No competing interests declared

  8. Genevieve L Wojcik

    Department of Genetics, Stanford University School of Medicine, Stanford, United States
    Contribution
    Investigation, Writing—review and editing
    Competing interests
    No competing interests declared

  9. Tielman Van Vleck

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Software, Validation, Investigation
    Competing interests
    No competing interests declared

  10. Janina M Jeff

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Data curation, Methodology
    Competing interests
    No competing interests declared

  11. Michael Linderman

    1. Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    2. The Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    Present address
    Department of Computer Science, Middlebury College, Middlebury, United States
    Contribution
    Resources, Software
    Competing interests
    No competing interests declared

  12. Claudia Schurmann

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Present address
    Department of Computer Science, Middlebury College, Middlebury, United States
    Contribution
    Resources, Data curation, Methodology
    Competing interests
    No competing interests declared

  13. Douglas Ruderfer

    1. Broad Institute, Cambridge, United States
    2. Division of Psychiatric Genomics, Icahn School of Medicine at Mt Sinai, New York, United States
    3. Center for Statistical Genetics, Icahn School of Medicine at Mt Sinai, New York, United States
    Present address
    Departments of Medicine, Psychiatry and Biomedical Informatics, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, United States
    Contribution
    Resources, Data curation, Methodology
    Competing interests
    No competing interests declared

  14. Xiaoqiang Cai

    Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Validation, Methodology
    Competing interests
    No competing interests declared

  15. Amanda Merkelson

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Data curation, Methodology, Project administration
    Competing interests
    No competing interests declared

  16. Anne E Justice

    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Data curation, Writing—review and editing
    Competing interests
    No competing interests declared

  17. Kristin L Young

    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Data curation, Writing—review and editing
    Competing interests
    No competing interests declared

  18. Misa Graff

    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Data curation, Writing—review and editing
    Competing interests
    No competing interests declared

  19. Kari E North

    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Project administration, Writing—review and editing
    Competing interests
    No competing interests declared

  20. Ulrike Peters

    1. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    2. Department of Epidemiology, University of Washington School of Public Health, Seattle, United States
    Contribution
    Project administration, Writing—review and editing
    Competing interests
    No competing interests declared

  21. Regina James

    National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, United States
    Contribution
    Project administration, Writing—review and editing
    Competing interests
    No competing interests declared

  22. Lucia Hindorff

    National Human Genome Research Institute, National Institutes of Health, Bethesda, United States
    Contribution
    Project administration, Writing—review and editing
    Competing interests
    No competing interests declared

  23. Ruth Kornreich

    Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Validation, Methodology
    Competing interests
    No competing interests declared

  24. Lisa Edelmann

    Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Validation, Methodology, Project administration
    Competing interests
    No competing interests declared

  25. Omri Gottesman

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Present address
    Regeneron Pharmaceuticals, Tarrytown, United States
    Contribution
    Conceptualization, Resources, Data curation
    Competing interests
    No competing interests declared

  26. Eli EA Stahl

    1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. The Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    3. Harris Center for Precision Wellness, Icahn School of Medicine at Mt Sinai, New York, United States
    4. Broad Institute, Cambridge, United States
    Contribution
    Resources, Formal analysis
    Competing interests
    No competing interests declared

  27. Judy H Cho

    1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    3. Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Resources, Project administration, Writing—review and editing
    Competing interests
    No competing interests declared

  28. Ruth JF Loos

    1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Resources, Data curation, Project administration, Writing—review and editing
    Competing interests
    Reviewing editor, eLife

  29. Erwin P Bottinger

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Present address
    Berlin Institute of Health, Berlin, Germany
    Contribution
    Conceptualization, Resources, Project administration
    Competing interests
    No competing interests declared

  30. Girish N Nadkarni

    The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    Contribution
    Formal analysis, Supervision, Writing—review and editing
    Competing interests
    No competing interests declared

  31. Noura S Abul-Husn

    1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    3. The Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    Present address
    Regeneron Pharmaceuticals, Tarrytown, United States
    Contribution
    Formal analysis, Validation, Writing—original draft
    Competing interests
    No competing interests declared

  32. Eimear E Kenny

    1. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, United States
    3. The Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    4. Center for Statistical Genetics, Icahn School of Medicine at Mt Sinai, New York, United States
    Contribution
    Conceptualization, Formal analysis, Supervision, Writing—original draft, Writing—review and editing
    For correspondence
    eimear.kenny@mssm.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9198-759X

Funding

National Human Genome Research Institute (U01HG009080)

  • Gillian Morven Belbin
  • Sumita Kohli
  • Eimear E Kenny

National Human Genome Research Institute (U01HG109391)

  • Gillian Morven Belbin
  • Sumita Kohli
  • Eimear E Kenny

National Human Genome Research Institute (U01HG007416)

  • Gillian Morven Belbin
  • Claudia Schurmann
  • Ruth Loos
  • Eimear E Kenny

National Human Genome Research Institute (U01HG007417)

  • Anne E Justice
  • Kristin L Young
  • Misa Graff
  • Kari E North

National Human Genome Research Institute (U01HG007397)

  • Christopher R Gignoux
  • Genevieve L Wojcik

National Human Genome Research Institute (U01HG007376)

  • Ulrike Peters

National Institute on Minority Health and Health Disparities (HHSN268201200008)

  • Gillian Morven Belbin
  • Elena P Sorokin
  • Christopher R Gignoux
  • Genevieve L Wojcik
  • Misa Graff
  • Kari E North
  • Ulrike Peters
  • Ruth Loos
  • Eimear E Kenny

National Human Genome Research Institute (HHSN268201200008)

  • Gillian Morven Belbin
  • Elena P Sorokin
  • Sumita Kohli
  • Christopher R Gignoux
  • Genevieve L Wojcik
  • Misa Graff
  • Kari E North
  • Ulrike Peters
  • Ruth Loos
  • Eimear E Kenny

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We would like to thank Noah Zaitlen, Alexander Gusev, George Diaz, Rounak Dey, and Alicia Martin for their helpful suggestions in preparing this manuscript. This work was supported by funds from several grants; The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute, with co-funding from the National Institute on Minority Health and Health Disparities, supported by U01HG007416, U01HG007417, U01HG007397, U01HG007376, and U01HG007419. The PAGE consortium thanks the staff and participants of all PAGE studies for their important contributions. The complete list of PAGE members can be found at http://www.pagestudy.org. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268201200008I. Genotype data quality control and quality assurance services were provided by the Genetic Analysis Center in the Biostatistics Department of the University of Washington, through support provided by the CIDR contract. High performance computing was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai and through the Office of Research Infrastructure under award number S10OD018522. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Ethics

Human subjects: Study participants were recruited from the BioMe Biobank Program of The Charles Bronfman Institute for Personalized Medicine at Mount Sinai Medical Center from 2007 onward. The BioMe Biobank Program (Institutional Review Board 07-0529) operates under a Mount Sinai Institutional Review Board-approved research protocol. All study participants provided written informed consent.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 5,131
    views
  • 381
    downloads
  • 62
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gillian Morven Belbin
  2. Jacqueline Odgis
  3. Elena P Sorokin
  4. Muh-Ching Yee
  5. Sumita Kohli
  6. Benjamin S Glicksberg
  7. Christopher R Gignoux
  8. Genevieve L Wojcik
  9. Tielman Van Vleck
  10. Janina M Jeff
  11. Michael Linderman
  12. Claudia Schurmann
  13. Douglas Ruderfer
  14. Xiaoqiang Cai
  15. Amanda Merkelson
  16. Anne E Justice
  17. Kristin L Young
  18. Misa Graff
  19. Kari E North
  20. Ulrike Peters
  21. Regina James
  22. Lucia Hindorff
  23. Ruth Kornreich
  24. Lisa Edelmann
  25. Omri Gottesman
  26. Eli EA Stahl
  27. Judy H Cho
  28. Ruth JF Loos
  29. Erwin P Bottinger
  30. Girish N Nadkarni
  31. Noura S Abul-Husn
  32. Eimear E Kenny
(2017)
Genetic identification of a common collagen disease in Puerto Ricans via identity-by-descent mapping in a health system
eLife 6:e25060.
https://doi.org/10.7554/eLife.25060

Share this article

https://doi.org/10.7554/eLife.25060

Categories and tags

Research organism

Further reading

    1. Developmental Biology
    2. Genetics and Genomics

    Caspar specifies primordial germ cell count and identity in Drosophila melanogaster

    Subhradip Das, Sushmitha Hegde ... Girish S Ratnaparkhi
    Research Article

    Repurposing of pleiotropic factors during execution of diverse cellular processes has emerged as a regulatory paradigm. Embryonic development in metazoans is controlled by maternal factors deposited in the egg during oogenesis. Here, we explore maternal role(s) of Caspar (Casp), the Drosophila orthologue of human Fas-associated factor-1 (FAF1) originally implicated in host-defense as a negative regulator of NF-κB signaling. Maternal loss of either Casp or it’s protein partner, transitional endoplasmic reticulum 94 (TER94) leads to partial embryonic lethality correlated with aberrant centrosome behavior, cytoskeletal abnormalities, and defective gastrulation. Although ubiquitously distributed, both proteins are enriched in the primordial germ cells (PGCs), and in keeping with the centrosome problems, mutant embryos display a significant reduction in the PGC count. Moreover, the total number of pole buds is directly proportional to the level of Casp. Consistently, it’s ‘loss’ and ‘gain’ results in respective reduction and increase in the Oskar protein levels, the master determinant of PGC fate. To elucidate this regulatory loop, we analyzed several known components of mid-blastula transition and identify the translational repressor Smaug, a zygotic regulator of germ cell specification, as a potential critical target. We present a detailed structure-function analysis of Casp aimed at understanding its novel involvement during PGC development.

    1. Genetics and Genomics

    Genetic inactivation of zinc transporter SLC39A5 improves liver function and hyperglycemia in obesogenic settings

    Shek Man Chim, Kristen Howell ... Regeneron Genetics Center
    Research Article

    Recent studies have revealed a role for zinc in insulin secretion and glucose homeostasis. Randomized placebo-controlled zinc supplementation trials have demonstrated improved glycemic traits in patients with type II diabetes (T2D). Moreover, rare loss-of-function variants in the zinc efflux transporter SLC30A8 reduce T2D risk. Despite this accumulated evidence, a mechanistic understanding of how zinc influences systemic glucose homeostasis and consequently T2D risk remains unclear. To further explore the relationship between zinc and metabolic traits, we searched the exome database of the Regeneron Genetics Center-Geisinger Health System DiscovEHR cohort for genes that regulate zinc levels and associate with changes in metabolic traits. We then explored our main finding using in vitro and in vivo models. We identified rare loss-of-function (LOF) variants (MAF <1%) in Solute Carrier Family 39, Member 5 (SLC39A5) associated with increased circulating zinc (p=4.9 × 10-4). Trans-ancestry meta-analysis across four studies exhibited a nominal association of SLC39A5 LOF variants with decreased T2D risk. To explore the mechanisms underlying these associations, we generated mice lacking Slc39a5. Slc39a5-/- mice display improved liver function and reduced hyperglycemia when challenged with congenital or diet-induced obesity. These improvements result from elevated hepatic zinc levels and concomitant activation of hepatic AMPK and AKT signaling, in part due to zinc-mediated inhibition of hepatic protein phosphatase activity. Furthermore, under conditions of diet-induced non-alcoholic steatohepatitis (NASH), Slc39a5-/- mice display significantly attenuated fibrosis and inflammation. Taken together, these results suggest SLC39A5 as a potential therapeutic target for non-alcoholic fatty liver disease (NAFLD) due to metabolic derangements including T2D.

    1. Genetics and Genomics
    2. Stem Cells and Regenerative Medicine

    A multiplexed, single-cell sequencing screen identifies compounds that increase neurogenic reprogramming of murine Muller glia

    Amy Tresenrider, Marcus Hooper ... Thomas A Reh
    Research Article

    Retinal degeneration in mammals causes permanent loss of vision, due to an inability to regenerate naturally. Some non-mammalian vertebrates show robust regeneration, via Muller glia (MG). We have recently made significant progress in stimulating adult mouse MG to regenerate functional neurons by transgenic expression of the proneural transcription factor Ascl1. While these results showed that MG can serve as an endogenous source of neuronal replacement, the efficacy of this process is limited. With the goal of improving this in mammals, we designed a small molecule screen using sci-Plex, a method to multiplex up to thousands of single-nucleus RNA-seq conditions into a single experiment. We used this technology to screen a library of 92 compounds, identified, and validated two that promote neurogenesis in vivo. Our results demonstrate that high-throughput single-cell molecular profiling can substantially improve the discovery process for molecules and pathways that can stimulate neural regeneration and further demonstrate the potential for this approach to restore vision in patients with retinal disease.